ceftolozane / tazobactam

This medicine is authorised for use in the European Union.


Zerbaxa is an antibiotic used to treat adults with:

  • complicated (difficult to treat) infections of tissues and organs within the belly (intra-abdominal infections); serious kidney infection (acute pyelonephritis);
  • complicated infections of the urinary tract (structures that carry urine, such as the bladder);
  • hospital-acquired pneumonia (an infection of the lungs that is caught in the hospital), including ventilator-associated pneumonia (pneumonia in patients using a ventilator, a machine that helps a patient to breathe).

Zerbaxa contains the active substances ceftolozane and tazobactam.

This EPAR was last updated on 10/03/2021

Authorisation details

Product details
Agency product number
Active substance
  • ceftolozane sulfate
  • tazobactam sodium
International non-proprietary name (INN) or common name
  • ceftolozane
  • tazobactam
Therapeutic area (MeSH)
Bacterial Infections
Anatomical therapeutic chemical (ATC) code
Publication details
Marketing-authorisation holder
Merck Sharp & Dohme B.V. 
Date of issue of marketing authorisation valid throughout the European Union
Contact address

Waarderweg 39
2031 BN Haarlem
The Netherlands

Product information

15/02/2021 Zerbaxa - EMEA/H/C/003772 - IAIN/0034


Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Antibacterials for systemic use

Therapeutic indication

Zerbaxa is indicated for the treatment of the following infections in adults:

  • Complicated intra abdominal infections;
  • Acute pyelonephritis;
  • Complicated urinary tract infections;
  • Hospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP).

Consideration should be given to official guidance on the appropriate use of antibacterial agents.

Assessment history

Related content

How useful was this page?

Add your rating
1 rating